RET alterations in thyroid cancer: Molecular mechanisms, targeted therapies, and emerging resistance.

Abstract excerpt

RET alterations, including RET fusions and RET mutations, have been identified in thyroid cancer. RET fusions are predominantly found in papillary thyroid carcinoma, whereas RET mutations are primarily associated with medullary thyroid carcinoma. Consequently, RET has emerged as an attractive therapeutic target. Previously, multikinase inhibitors, such as vandetanib and cabozantinib, were primarily used for...

Topics

• Humans
• Proto-Oncogene Proteins c-ret
• Thyroid Neoplasms
• Drug Resistance, Neoplasm
• Molecular Targeted Therapy
• Protein Kinase Inhibitors